| Literature DB >> 34209536 |
Nesrein M Hashem1, Antonio Gonzalez-Bulnes2.
Abstract
Reproductive efficiency of farm animals has central consequences on productivity and profitability of livestock farming systems. Optimal reproductive management is based on applying different strategies, including biological, hormonal, nutritional strategies, as well as reproductive disease control. These strategies should not only guarantee sufficient reproductive outcomes but should also comply with practical and ethical aspects. For example, the efficiency of the biological- and hormonal-based reproductive strategies is mainly related to several biological factors and physiological status of animals, and of nutritional strategies, additional factors, such as digestion and absorption, can contribute. In addition, the management of reproductive-related diseases is challenged by the concerns regarding the intensive use of antibiotics and the development of antimicrobial resistant strains. The emergence of nanotechnology applications in livestock farming systems may present innovative and new solutions for overcoming reproductive management challenges. Many drugs (hormones and antibiotics), biological molecules, and nutrients can acquire novel physicochemical properties using nanotechnology; the main ones are improved bioavailability, higher cellular uptake, controlled sustained release, and lower toxicity compared with ordinary forms. In this review, we illustrate advances in the most common reproductive management strategies by applying nanotechnology, considering the current challenges of each strategy.Entities:
Keywords: antibiotics; bio stimulation; hormones; livestock; nano-delivery system; nutrition; reproductive diseases; reproductive management
Year: 2021 PMID: 34209536 PMCID: PMC8300313 DOI: 10.3390/ani11071932
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Figure 1Possible applications of an aerosol nano-delivery system in pheromones-dependent sexual bio stimulation (male effect).
Characteristics and expected advances by the implementation of nanotechnologies in the use of reproductive hormones for farm animals’ reproductive management.
| Figure | Technique | Particle Characteristics | Expected Advances |
|---|---|---|---|
| GnRH-chitosan-TPP NPs [ | Ionic-gelation | Size = 212 nm, PdI = 0.295, |
Optimizing route of administration Decreasing dosage Increasing bioavailability Increasing animal welfare |
| GnRH-chitosan-TPP NPs [ | Size = 93.91 nm, PdI = 0.302, | ||
| GnRH-chitosan-dextran sulfate NPs [ | Ionic-gelation | EE = 40−50% | |
| hCG-chitosan-TPP NPs [ | Ionic-gelation | - | |
| P4-chitosan-TPP-Tween 80 [ | Spray-drying | Size = 1 and 7 μm, EE = 69–75% |
Improving environmental and human health |
| P4-polymethyl-methacrylate-nanospheres [ | Miniemulsion polymerization | size = 150–200 nm, EE > 69% | |
| P4-polymethyl-methacrylate-nanocapsules [ | size = 240–300 nm, EE > 90% | ||
| P4-polylactic acid NPs [ | Solution blow spinning | Size = 289–441 nm | |
| Melatonin-loaded lipid-core Nps [ | Interfacial deposition of polymer | size = 168 nm |
Enhancing quality and increasing production rates of bovine blastocysts produced by in vitro fertilization |
| Melatonin loaded-lipid (olive oil) NPs [ | Hot homogenization-ultrasonication | Size = 119nm, PdI = 0.09, EE = 94% |
Sustained release during IVF |
GnRH = gonadotropin releasing hormone, TPP = tripolyphosphate, NPs = nanoparticles, hCG = human chorionic gonadotropin, P4 = progesterone, PdI = polydispersity, Zp = zeta potential, and EE = encapsulation efficiency, and IVF = in vitro fertilization.
Figure 2Two-days ovulation points (red arrows) and growing follicles (blue arrows) in ovaries of control rabbits or those treated with 25 IU equine chorionic gonadotropin (eCG) or 0.2µ gonadotropin-releasing hormone (GnRH)-chitosan- tripolyphosphate (TPP) nanoparticles. Higher numbers of growing follicles and ovulation points and larger diameters of ovulation points could be observed in GnRH-chitosan-TPP nanoparticles (unpublished data).
Characteristics and expected advances by the implementation of nanotechnologies in nutritional management for farm animals’ reproductive management.
| Formula | Technique | Particle Characteristics | Expected Advances |
|---|---|---|---|
| Zinc oxide NPs [ | Commercial product | Size = 30.92 nm |
Increase bioavailability and reduce the negative effects of toxic concentrations in in vitro reproductive assisted techniques |
| Selenium oxide NPs [ | Commercial product | Size = 78.47 nm | |
| Selenium oxide NPs [ | Chemical reduction method using ascorbic acid and acacia gum | Size = 45.00 nm |
Increase absorption and bioavailability and reduce the negative effects of toxic concentrations during late pregnancy |
| Fish oil or soy oil -in-water NPs | Nanoemulsion | - |
Improve post-ruminal supply of PUFA Decreased transformation rate of PUFA to SFA in the bio-hydrogenation environment |
| Solid lipid-lysine NPs [ | Ultrasonic processor | Size = 200–500 nm |
Improve post-ruminal supply of lysine amino acid |
| Alginate-chitosan-glycerol NPs [ | Ionic-gelation | Size = 3 mm |
Encapsulating glycerol to bypass rumen fermentation |
Nps = nanoparticles, Zp = zeta potential, EE = encapsulation efficiency, PUFA = poly unsaturated fatty acids, and SFA = saturated fatty acids.
Summary of studies on the nano drugs developed to treat reproductive-related diseases.
| Type of Drug | Formula | Technique | Particle Characteristics | Drug Activity | Usage |
|---|---|---|---|---|---|
| Antibiotic [ | Enrofloxacin- | - | Size = 102 nm | Antimicrobial agent against | Endometritis and mastitis treatment |
| Antibiotic [ | Tilmicosin-loaded hydrogenated castor oil NPs | Hot homogenization and ultrasonication | Size = 343 nm | Antimicrobial agent against | Mastitis treatment |
| Antibiotic [ | Triclosan-loaded liposome NPs | Dehydration-rehydration | Size = 53.3 nm | Antimicrobial agent against | Toxoplasmosis treatment |
| Antibiotic [ | Atovaquone-poloxamer 188 - sodium dodecyl sulfate | - | - | Antimicrobial agent against | Toxoplasmosis treatment |
| Nitric oxide (NO) [ | NO-alginate-chitosan | - | Size= 270–375 nm | Antimicrobial agent against | Mastitis treatment |
| Metal [ | Silver NPs | Biosynthesis by apigenin | Size = 10 nm | Antimicrobial agent against | Antibiotic alternative for endometritis treatment |
| Metal [ | Silver NPs | Biosynthesis by quercetin | Size = 20 nm | Antimicrobial agent against | Antibiotic alternative for mastitis treatment |
| Chitosan [ | Chitosan-TPP Nps | Ionotropic gelation | Size = 19.1 nm | Antimicrobial agent against | Antibiotic alternative for mastitis treatment |
| Antibiotic + polyphenol [ | Poly(lactic-co-glycolic) acid-epigallocatechin gallate- doxycycline Nps | Modified double emulsion solvent evaporation/extraction technique | Size = 176 to 211 nm | Anti-inflammatory agent | Assisted-endometritis therapy |
| Essential oil 1 | Oregano oil Nps | - | - | Antimicrobial agent against | Antibiotic alternative for endometritis treatment |
Nps = nanoparticles, Zp = zeta potential, PdI = Polydispersityindex, and EE = encapsulation efficiency.1 https://patents.google.com/patent/CN104288222A/en; accessed on 12 February 2021.